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Abstract: Over 50% of patients who seek treatment for allergies present with ocular   symptoms. 
Our current ability to control ocular allergic symptoms is greater than ever before. Newer dual-
acting topical eyedrops attack multiple facets of the allergic cascade. Azelastine has antihistaminic 
effects providing immediate relief, mast cell stabilization providing early-phase intervention, 
and inhibition of expression and activation of anti-inflammatory mediators which characterize 
the late phase of the immune reaction. The ophthalmic eyedrop formulation is approved for 
treatment of allergic conjunctivitis in adults and children aged over 3 years. In clinical trials 
comparing azelastine with other dual-acting eyedrops, such as levocabastine and olopatadine, 
azelastine was reported to be slightly less efficacious and to sting briefly upon administration. 
Even so, many patients experienced the full benefit of symptom relief, and preferred azelastine. 
As a broad-spectrum drug, azelastine offers many desirable properties for management of ocular 
allergies. Because it can often produce maximal effect with just twice-daily dosing, azelastine is 
a particularly good choice for the allergic population in whom minimizing exposure to topical 
products and preservatives is a key concern.
Keywords: allergic conjunctivitis, dual acting anti-inflammatory, H1 receptor antagonism, mast 
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Introduction
More than 50 million Americans seek treatment for allergies annually, and over 
half of these patients present with ocular symptoms.1 Allergy commonly attacks the 
  conjunctival mucosa, as well as the nose, sinuses, ears, upper airways, and lungs. 
Remarkably, the ocular component may be the most common and initially the most 
prominent life-altering symptomatic complaint. Seasonal or episodic allergy patients 
become ill for only a few weeks or days, while others have symptoms persisting 
throughout the year or their entire lifetime.
The associated health care costs related to allergic conjunctivitis are often comingled 
with allergic rhinitis, and have been reported to be as high as $6 billion in the US, 
with 25% of that amount due to medication costs.2,3 Fiscal outlays attributed to ocular 
prescription medication have risen rapidly in the past generation, from $6 million in 
1990 to $200 million recently, with projected sustained growth of over 20% per year. 
Remarkably, this prescription growth is unique in that it is not commensurate with the 
aging of the population, but is concomitant with population growth. The prescription 
growth is due in part to vastly improved medication efficacy and its obvious superiority 
over less specific, less potent, and more toxic over-the-counter products. The actual 
cost of the medications and their relative price increases have continued recently on Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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a yearly basis, while a wide variety of formerly proprietary 
allergy medications have gone generic, or over-the-counter, 
with blossoming direct-to-consumer campaigns. With these 
numbers in mind, it is clear that cost-effective care for ocular, 
cutaneous, and respiratory allergy is a valuable asset.
Allergic conjunctivitis has several clinical hallmarks. 
Most patients experience acute attacks of red, irritated eyes 
with an intense feeling of itching that result in tearing. These 
episodes are often accompanied by clinical signs of lid edema, 
conjunctival chemosis, and papillary reactions that can be 
appreciated on examination. The underlying pathophysiol-
ogy originates from the body’s natural immune reactions. 
  Conjunctival tissue harbors numerous mast cells that are filled 
with histamine and other inflammatory components. Due to 
the priming mechanisms of mast cells, previous sensitivities 
to specific allergens cause antibodies to form against these 
allergens. These antibodies are highly integrated into the cell 
surface of the mast cells. Then, upon re-exposure of the tissue 
to the allergen, the surface antibodies on mast cells initiate a 
cascade of events that results in the release of their granular 
contents. These agents are the inciting factors for the classic 
symptoms of allergic conjunctivitis. The early phase of the 
allergic reaction is due to histamine-induced vasodilation that 
results in redness and fluid collection in the form of lid edema 
and chemosis, and also causes the classic symptom of pruri-
tus. The release of other inflammatory mediators from mast 
cells recruits additional mediators to the site, consequently 
sustaining the late phase of the allergic reaction. Thus, the 
symptomatology of allergic conjunctivitis centers around 
the effects of histamine and inflammatory mediators on the 
surrounding ocular tissues. Given the multitude of mediators 
involved, drugs like azelastine (Optivar®; Bausch and Lomb, 
Rochester, NY) that counteract several steps along this pathway 
can provide clinically efficacious treatment of patients with 
allergic conjunctivitis.
For ocular allergies, the latest generation of topical anti-
allergic medications possesses multiple actions that include 
antihistaminic effects to provide immediate relief, early-
phase intervention through stabilization of activated mast 
cells, and additional late-phase reactant inhibition without 
the customary topical or systemic steroid side effect profiles.4 
Azelastine, a member of this newest generation, has multiple 
effects as an antihistamine, mast cell stabilizer, and inhibitor 
of inflammatory mediators. Azelastine was first approved in 
1996 as a nasal spray to treat symptoms of seasonal allergic 
disease and in 1999 for nonallergic vasomotor rhinitis. An 
ophthalmic eyedrop formulation for the treatment of aller-
gic conjunctivitis in adults and children over three years 
of age received Food and Drug Administration approval in 
May 2000.5
Pharmacology of azelastine
Chemical classification
Azelastine is a selective, nonsedating H1 antagonist with 
structural similarities to other antihistamines. As a phthalazi-
none derivative with a seven-membered ring, it is commonly 
used as an anhydrous monohydrochloride salt (Figure 1). 
The white, odorless, bitter-tasting crystalline powder is a 
racemic mixture of azelastine hydrochloride, with a high 
melting point of 225°C. Even as a hydrochloride salt, the 
small organic molecule is only sparingly soluble in methanol, 
propylene glycol, and water, but slightly soluble in glyc-
erin, ethanol, and octanol. Although azelastine is soluble in 
dichloromethane and in chloroform, these solvents are not 
well tolerated in pharmaceutical preparations.
Dosage form
Although azelastine is orally active, it is most often admin-
istered topically, either as a nasal spray or as a sterile 
ophthalmic solution. The ophthalmic solution is not light-
sensitive and is stable for up to two years when packaged in 
an unopened dropper bottle and stored upright at 35–75°F. 
Once opened, the unused contents should be discarded after 
one month.
Azelastine ophthalmic solution (0.05%) is preserved with 
benzalkonium chloride (BAK). The toxic effects of BAK 
on the cornea are well documented.6 In the concentration 
used here (BAK 0.125%), prolonged use of topical eye-
drops containing BAK is associated with well documented 
deleterious effects on the conjunctiva and cornea, as well 
as the quality and quantity of tear film. Because BAK may 
be absorbed by soft contact lenses, patients should not 
insert contact lenses for at least 10 minutes after instilling 
azelastine eyedrops. In addition to BAK, the aqueous vehicle 
is composed of ingredients commonly used in generally 
well tolerated eyedrops. The vehicle includes disodium 
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  ethylenediaminetetraacetic acid, hypromellose, sorbitol 
solution, and sodium hydroxide   buffered to pH 5.0–6.5; 
osmolarity is about 300 mOsmol/L.
About one third of patients remark that azelastine eye 
drops sting transiently upon instillation. This irritating effect 
may be due to the low pH or, more probably, due to intrinsic 
irritating effects of azelastine on the ocular epithelium.4 
Chemical properties of azelastine may directly cause irrita-
tion of ocular tissues after topical administration. Conjuncti-
val cell damage by topical antiallergic drugs can be measured 
in cultured rabbit conjunctiva using the lactate dehydrogenase 
assay. In comparison with olopatadine (Patanol®; Alcon, Fort 
Worth, TX), both azelastine and ketotifen increased lactate 
dehydrogenase titers, edema, and cell degeneration, which is 
reflected in the clinical data discussed in this review.7
Multiple mechanisms of action
Azelastine is classified pharmacologically as a second-
generation antihistamine, ie, it is a relatively selective, 
nonsedating, competitive antagonist at H1 receptors. Its 
relative lack of central nervous system activity distinguishes 
it from first-generation antihistamines. Inhibition of inflam-
matory mediators, in addition to antihistaminic and mast cell 
stabilizing effects, place it among the new generation of dual-
acting anti-inflammatory drugs. In addition to azelastine’s 
high affinity for H1 receptors, its ability to modify several 
other mediators of inflammation and allergy contributes to 
its mechanism of action.8 In vitro and in vivo studies, as well 
as the clinical trials discussed here, support the dual effects 
of direct inhibition and stabilization of inflammatory cells 
(Figure 2).
In vitro data indicate that azelastine’s affinity for H1 
receptors is estimated to be several times greater than that 
of chlorpheniramine, a first-generation H1 antagonist.9 
Azelastine has only weak affinity for H2 receptors. Release 
of histamine from mast cells is also inhibited possibly by 
reversible inhibition of voltage-dependent L-type calcium 
channels.10 Inhibition of mast cell degranulation may also 
decrease the release of other inflammatory mediators, includ-
ing leukotrienes and interleukin-1β, among others. Azelastine 
also directly antagonizes other mediators of inflammation, 
such as tumor necrosis factor-α, leukotrienes, endothelin-1, 
and platelet-activating factor.11,12
Conjunctival mast cells play a prominent role in allergic 
conjunctivitis. Due to its multiple mechanisms, azelastine 
mediates both immediate- and late-phase allergic reactions 
associated with mast cell degranulation.13 By directly antago-
nizing the effects of histamine released from mast cells, 
azelastine modifies immediate allergic responses typified 
by pruritus, hyperemia, edema, and chemosis. Activation of 
H1 receptors on nerve tissue causes pruritus, while activa-
tion of H1 receptors on vascular tissue causes hyperemia and 
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Figure 2 Multiple pathways are responsible for the antiallergic effects of azelastine. 
The figure summarizes the pathways of action of multiple action antiallergic drugs, which include membrane activation and cell degranulation (early phase reaction) and de-novo 
synthesis (late-phase reaction). Drugs acting at the membrane level also interfere with the subsequent steps of intracellular Ca2+ influx and PTK signal transduction pathway. 
Copyright © 2009, Lippincott Williams & Wilkins. All rights reserved. Adapted with permission from Lambiase A, Micera A, Bonini S. Multiple action agents and the eye: do 
they really stabilize mast cells? Curr Opin Allergy Clin Immunol. 2009;9(5):454–465. 
Abbreviations: lgE, immunoglobulin E; MC, mast cell; NGF, nerve growth factor; PTK, protein-tirosyne kinase; VEGF, vascular endothelial growth factor.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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edema. Through both IgE-dependent and IgE-independent 
inhibition of mast cell degranulation, azelastine diminishes 
the second wave of newly generated biochemical mediators 
that increase mucus secretion and promote infiltration of 
inflammatory cells. Azelastine minimizes ocular surface 
damage through inhibition of immune cells that characterize 
the late-phase immune reaction, including downregulation of 
intercellular adhesion molecule (ICAM)-1 on conjunctival 
epithelial cells.14
In vivo studies in a guinea pig model showed that both 
histamine-related and histamine-independent bronchocon-
striction were inhibited by azelastine.8 Furthermore, vascular 
extravasation was reduced by azelastine in sensitized guinea 
pig and rat models. Both immediate- and late-phase responses 
were inhibited by azelastine in a mouse model sensitized 
by dintrofluorobenzene. Azelastine retains its efficacy over 
a sustained period of time. Regular daily use has not been 
associated with tachyphylaxis due to downregulation of H1 
receptors or their antagonism.15
Pharmacokinetics
Absorption and distribution
Azelastine is well absorbed after oral administration.16 
Plasma concentrations were linear over the dosage 
range (2.2–17.6 mg). Both the time to maximum plasma 
concentration (tmax 4.6 hours) and elimination half-life 
(t1/2 25.0 ± 5.2 hours) were independent of dose.17,16 The 
large interindividual variation is likely due to differ-
ences in enterohepatic circulation of this lipid-soluble 
drug. Similarly, following intravenous administration, the 
t1/2 was 22 hours, volume of distribution at steady state 
was 14.5 L/kg, and plasma clearance was 0.5 L/h/kg 
(see http://dailymed.nlm.nih.gov). Plasma protein binding 
(88% of unmetabolized drug) is extensive.
By comparison, following ocular administration, systemic 
absorption of azelastine is minimal. After 56 days of topi-
cal treatment two to four times daily, plasma concentrations 
were only 0.2–0.25 ng/mL. These low plasma concentrations 
decrease the probability of systemic adverse effects, and also 
imply that the response to azelastine eyedrops is due to a local 
effect on ocular tissue. Using an allergen challenge design,18 
azelastine had an onset of action within three minutes, and 
the effects lasted at least 8–10 hours.
Metabolism and elimination
After oral administration, N-desmethylazelastine, the primary 
active metabolite of azelastine, is produced in the liver largely 
by CYP450, CYP3A4, and CYP2D619 (Figure 1). Lesser 
amounts of two inactive carboxylic acid metabolites are also 
produced.20 The t1/2   of N-desmethylazelastine (54 hours) is 
more than twice as long as azelastine, and contributes greatly 
to its long duration of action after systemic administration. 
Severe adverse effects have been reported for antihistamines 
that are metabolized by the liver, which provides a cogent 
argument for topical administration. Topical azelastine 
eyedrops, administered to the target organ, permit applica-
tion of relatively small doses. About 75% of azelastine is 
excreted in the feces, and more than 90% is in the form of 
N-desmethylazelastine, its primary metabolite.21
Less than 25% of azelastine and its metabolite is excreted 
in the urine, but in patients with compromised renal func-
tion (ie, Ccr , 50 mL/min), the plasma concentrations can 
increase by up to 75%. The implication of declining renal 
function is noted in patients older than 65 years, in whom 
oral administration increased the t1/2 to 38 ± 15.3 hours, with 
a concomitant doubling of the Cmax.17 Given the long t1/2 of 
N-desmethylazelastine, it too would be expected to accumu-
late and further extend the duration of action, particularly 
during multiple dosing, as is common in the treatment of 
allergic conjunctivitis. Despite the potential for increased 
plasma concentration and duration of action, azelastine is 
well tolerated in older patients. Given that systemic absorp-
tion of azelastine after topical administration is minimal, most 
elderly patients tolerate this form of administration very well. 
Likewise, in placebo-controlled studies, both topical ocular 
and nasal administration of azelastine are well tolerated in 
children aged 5–12 years.22,23
Drug interactions
Concomitant administration of more than one medication can 
precipitate severe adverse effects. Many clinically relevant 
drug interactions are due to unexpectedly increased plasma 
concentrations of one or both drugs, when both are metabolized 
by the same CYP450 enzymes. Of particular concern are the 
arrhythmogenic changes in the QTc interval when an antihis-
tamine, such as terfenadine, is administered orally along with 
either ketoconazole or erythromycin.24 Even though azelastine 
is more than 90% metabolized by CYP3A4 and CYP2D6, and 
to a lesser extent by CYP1A2,19 such drug interactions are 
unlikely to be due to the low plasma concentration of azelastine 
and N-desmethylazelastine after topical administration.
Carcinogenesis, mutagenesis, and fertility
Oral doses in mice have demonstrated carcinogenicity, muta-
genicity, and fetotoxicity in mice at doses of 68.6 mg/kg, 
which is 57,000 times greater than the recommended dose for Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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topical eyedrops in humans (see http://dailymed.nlm.nih.gov). 
The pregnancy category is C. There are no well   controlled 
studies of topical application in pregnant women. Likewise, the 
extent of azelastine excretion in human breast milk is unknown. 
Considering that other lipophilic drugs are excreted in breast 
milk, it is likely that azelastine and its active metabolite are 
too. Given the lack of definitive data, azelastine should be 
used with great caution in pregnant or nursing women only if 
the benefit is deemed to be far greater than the potential risk 
to the progeny.
Efficacy and tolerability studies
An early study demonstrated that azelastine not only has a rapid 
onset of action, but also has a protective effect when adminis-
tered prior to allergen exposure.25 This double-masked, placebo-
controlled trial included 20 subjects with known Parietaria 
judaica sensitivity, which was confirmed with a skin prick test 
to determine the concentration needed to elicit a conjunctival 
response reproducibly. In the first arm of the study, the allergen 
was instilled into both eyes. The response was scored every 5 
minutes for 20 minutes before and for 30 minutes after instil-
lation of either azelastine or placebo. The score was based on 
clinical evaluation of conjunctival hyperemia, itching, lacrima-
tion, and eyelid swelling. Compared with placebo, azelastine 
significantly reduced the symptoms within 10–20 minutes.25 
The prophylactic effect of azelastine was demonstrated by com-
paring the response to the allergen challenge after seven days 
of twice-daily administration of azelastine with placebo. There 
were no reported adverse effects and the azelastine drops were 
well tolerated. The scores were recorded 5, 10, 20, and 30 min-
utes (early-phase reaction), and 6 hours (late-phase reaction) 
after allergen exposure. As with the first experiment, compared 
with placebo, azelastine significantly reduced symptom scores 
during both the early- and late-phase reactions. In addition, 
impression cytology demonstrated that azelastine significantly 
decreased both inflammatory cell infiltration and ICAM-1 
expression during both the early- and late-phase reactions. 
Both subjective (symptom scores) and objective (impression 
cytology) parameters established the antiallergic activity of 
azelastine in the eye, and confirmed its inhibitory effect on 
infiltration of inflammation and downregulation of ICAM-1, 
which was first observed in the nasal mucosa.14
This initial trial supported further investigation into the 
efficacy and safety profiles of azelastine. In a dose-ranging 
trial, 151 patients with at least one year of allergic conjunc-
tivitis symptoms were randomized to three groups receiving 
either placebo, or 0.025% or 0.05% azelastine twice daily 
for 14 days.26 After seven and 14 days of treatment, patients’ 
symptoms were scored by the investigators on a four-point 
scale for presence and intensity of itching, lacrimation, 
and conjunctival erythema. Much like the previous study, 
azelastine effectively decreased symptoms of allergic con-
junctivitis. Comparing the two strengths, 0.05% azelastine 
was significantly more effective than 0.025% azelastine 
(82% responders versus 73%, respectively). No serious 
adverse events were reported in any of the three treatment 
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Figure 3 Azelastine topical eye drops cause a sustained decrease in allergic symptoms. Copyright © 2003. Reproduced with permission from Nazarov O, Petzold U, Haase H, 
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groups. However, in contrast with the initial trial, the inci-
dence of treatment-related adverse effects in the azelastine 
treatment groups was 30.5%. The two most frequently 
reported adverse effects were burning sensation in the eyes 
after drug application and a bitter taste. Taste perversion is 
thought to be the result of the medication draining from the 
lacrimal system through the nares and then onto the posterior 
surface of the tongue.
After the efficacy of azelastine was established, further 
studies investigated the onset and duration of effectiveness of 
azelastine in patients with allergic conjunctivitis.18 Patients 
with at least a 2-year history of allergic conjunctivitis, a posi-
tive allergen skin test, and two separate positive responses to 
a conjunctival allergen were enrolled in a randomized, blinded 
clinical trial (n = 80). Twenty minutes prior to exposure to 
the known conjunctival allergen, one eye was treated with 
placebo and the contralateral eye with azelastine 0.05%. 
Using a five-point scale, the investigators rated the extent of 
chemosis and conjunctival redness. The patients also assessed 
the extent of itching and tearing using the same scale. After 
a 7-day washout period, the test was repeated, except that 
the drops were administered 8–10 hours before exposure to 
the allergen. The results from both experiments confirmed 
that azelastine was highly effective in decreasing allergic 
conjunctivitis symptoms, including itching, conjunctival 
redness, tearing, and chemosis. Onset of action was rapid, 
occurring within 3 minutes of allergen exposure. Azelastine 
inhibited development of symptoms for at least 8–10 hours 
after instillation, suggesting a long duration of action and 
supporting twice daily administration.
A third double-masked, randomized, placebo-controlled 
study evaluated the efficacy of azelastine during extended 
treatment.27 Patients were randomized to either placebo or 
azelastine (0.05%) treatment groups (n = 16 each) and fol-
lowed for 42 days. Following 7, 21, and 42 days of treatment, 
investigators examined the patients and rated the extent 
of conjunctival redness and itchy sensation on a scale of 
0–6. The sum score of symptoms showed significant rapid 
improvement in the azelastine group compared with the 
placebo group, with continued improvement even up to day 
42 (Figure 3).27 After 7 days, 55% in the azelastine group 
had significant score improvement versus 15% in the placebo 
group. After 42 days, the response rate increased to 95% 
for azelastine versus 33% for placebo. The adverse effect 
profile reported by patients was similar to that reported in 
other trials. The two most common complaints were taste 
perversion and a mild stinging or burning sensation after 
drop administration. In this trial, a slightly larger proportion 
of patients (22%) commented on a bitter taste after azelastine. 
However, patients also reported 97% tolerability. The very 
high level of tolerability suggests that the relief of symptoms 
far outweighs any taste perversion. While confirming that 
azelastine effectively decreases symptoms of treatment for 
allergic conjunctivitis, this trial established that azelastine also 
provides sustained benefit and is well tolerated over time.
Children comprise a large portion of the patient population 
presenting with allergic symptoms. Once safety and efficacy 
were established in adults, a separate trial was conducted in 
children.22 A double-masked, multicenter study compared the 
effectiveness of azelastine (0.05%) on seasonal conjunctivitis 
and rhinoconjunctivitis, with that of placebo or levocabastine 
0.05%. The children, aged 4–12 years, were randomized into 
three treatment groups (n = 113 each). All drops were admin-
istered bilaterally twice daily in the morning and evening for 
14 days. On days 3 and 14, the investigators evaluated the 
effectiveness of the medication by scoring three main symp-
toms, ie, eye itching, lacrimation, and conjunctival redness, 
on a four-point scale. Patients also kept a journal to document 
their daily symptoms using the same scale. By comparing 
mean scores for the three treatment groups, it was clear that 
the two drug treatments were superior to placebo from both 
the clinicians’ and patients’ perspectives. In the investigator-
collected data, treatment was considered satisfactory in 39% 
of the placebo group, 74% of the azelastine group, and 84% 
of the levocabastine group. According to the subjects’ scores, 
the azelastine (72%) and levocabastine (71%) treatments were 
far superior to the placebo treatment (41%). No statistically 
significant difference was found between the azelastine and 
levocabastine groups; both were far superior in treatment 
response than placebo. The adverse effect profile for azelastine 
reflected that reported in trials with adult patients. The most 
common adverse effect was a burning or tingling sensation 
after application of the drops in 33%–34% of the azelastine 
group, 38% of the levocabastine group, and 17% of the pla-
cebo group. A bitter taste was reported by two patients. This 
study confirmed that the safety and efficacy of azelastine in 
children was similar to that reported in adult patients.
Comparison with other topical 
antihistamines
After the safety, efficacy, and tolerability of azelastine were 
established, other trials were conducted to compare its effec-
tiveness and tolerability with that of other similar drugs. 
A single-masked, multicenter study compared azelastine 
0.05% with another topical antihistamine, levocabastine, 
and placebo.28 Patients were divided into three treatment Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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groups and treated twice daily for 6 weeks (n = 139). Before 
beginning the six-week trial, all subjects underwent a 1-week 
trial with placebo. Only those subjects who scored $3 or on 
a 0–6-point scale for conjunctival redness and itching were 
then randomized to one of the three treatment groups. The 
subjects were evaluated on days 7, 21, and 42 of treatment 
using the same scale. The treatment response was evaluated 
by comparing change in symptom score after each treatment 
evaluation with the initial 1-week placebo score.28 Azelastine 
and levocabastine decreased conjunctival redness and itch-
ing by a similar amount, but both were significantly more 
efficacious than placebo. Because both medications produced 
very similar responses, the authors concluded that azelastine 
was at least as effective as levocabastine in treating allergic 
conjunctivitis.
Adverse effects
When compared with levocabastine over a six-week period, 
adverse effects reported by the azelastine treatment group 
were application site reaction (26.3%), taste perversion 
(10.5%), and conjunctivitis (1.8%).28 By comparison, 15.4% 
of levocabastine users reported application site reaction and 
no taste changes or conjunctivitis, and only 5.4% of placebo 
users reported an application site reaction. Thus, the study 
results yielded two main conclusions, ie, that azelastine and 
levocabastine both significantly improve patients’ symptoms 
with comparable efficacy, and that the incidence of adverse 
effects is greater during treatment with azelastine.
Because olopatadine is another major drug in this class, 
comparison of azelastine and olopatadine is essential for 
fully understanding azelastine’s place among the therapeutic 
options. Both are highly efficacious, although their effects may 
differ somewhat at a cellular basis.5 There are several studies 
comparing their clinical effectiveness. Spangler et al29 used 
a similar conjunctival allergen challenge model to that used 
by Friedlaender et al in 2000.18 In this   prospective, double-
masked trial, 111 subjects were randomized into three groups, 
ie, one eye treated with azelastine and the contralateral eye 
treated with olopatadine, one eye treated with azelastine and 
the other placebo (artificial tears), and one eye treated with 
olopatadine and the other placebo (artificial tears). All eyes 
were confirmed on the first visit to have a bilateral allergic 
response to a known allergen, increasing the concentration 
until a positive reaction was elicited. On visit 2, all eyes were 
challenged with the allergen to establish the intensity of their 
response. At a third visit, eyes were pretreated with azelastine, 
olopatadine, or placebo five minutes before administration 
of the previously determined allergen. Patients then rated 
the intensity of itching on a scale of 0–4 at 30-second inter-
vals over a total of 20 minutes. The mean itching scores of 
eyes treated with azelastine, olopatadine, and placebo were 
then compared. Although both azelastine and olopatadine 
controlled itching after allergen exposure significantly bet-
ter than placebo, olopatadine was significantly more effec-
tive than azelastine beginning at 3.5 minutes after allergen 
exposure and for the duration of the 20-minute test period. 
Although this was a short time period, in this study olopa-
tadine appeared to be more efficacious than azelastine for 
allergic conjunctivitis.
The recent major multicenter, prospective, open-label 
PACE (Pataday Allergic Conjunctivitis Evaluation) study 
compared olopatadine 0.2% once daily with azelastine 
0.05% twice daily.1 Patients with allergic conjunctivitis 
who had recently used azelastine completed a questionnaire 
evaluating their previous azelastine medication (n = 49). All 
patients then replaced azelastine with olopatadine 0.2% once 
daily, and completed a similar survey about their experience 
with olopatadine seven days later. There were no differences 
between the two drugs in those patients who found them only 
somewhat effective. However, more patients (42%–46%) 
reported that olopatadine improved itching and redness 
more effectively than azelastine (17%–20%). Drop comfort, 
ease of use, speed of relief, and overall satisfaction were 
rated significantly higher by those who found olopatadine 
to be very effective. Although both medications decreased 
symptoms of allergic conjunctivitis, olopatadine was rated 
higher for efficacy and tolerability by patients who received 
the greatest symptomatic relief. Epinastine (Elestat®; Inspire 
Pharmaceuticals, Raleigh, NC) was rated more comfortable 
than azelastine in other research.30
Azelastine in clinical practice
Our current ability to control allergic symptoms is greater 
than ever before. Our knowledge and the tools at our disposal 
are now substantial, including potent, multimechanism agents 
specifically targeting the allergic response. Isolated ocular 
allergy is usually very responsive to carefully selected topi-
cal medications.
More effective newer antihistamine products with mul-
tiple antiallergic mechanisms are now available. Most of these 
newer antihistamines can also stabilize mast cell membranes 
and thereby exert both indirect and direct effects on immune 
cells.8 The newer agents reduce application frequency and 
have the advantage of rapid therapeutic onset. The first such 
drug, olopatadine, established new records for ophthalmic 
pharmaceutical sales in the US, and is the standard with Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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which other drugs in this class are compared. Newer drugs 
in this category include azelastine, epinastine, ketotifen 
(Zaditor®; Novartis and Alway, Bausch and Lomb), bepotas-
tine 1.5% (Bepreve®; Ista Pharmaceuticals, Irvine, CA), and 
nedocromil (Alocril®; Allergan, Irvine, CA).
Topical multimechanism agents also enhance efficacy by 
inhibiting key cellular components of the allergic response.4 
As potent mast cell stabilizers, they inhibit subsequent 
IgE/antigen-mediated release of histamine and other pre-
formed chemical mediators that both produce acute allergic 
symptoms and contribute to the inflammatory response 
accompanying ocular allergy.13,8 Furthermore, they can also 
mitigate the delayed hypersensitivity reaction by inhibiting 
the activity of proinflammatory cells and cytokines, as well 
as the expression of cell surface adhesion molecules that are 
important in eosinophil diapedesis.
Methodic evaluation is critical in the patient with ocular red-
ness and a chief complaint of itching to ascertain the differential 
diagnosis of either seasonal or perennial acute allergic conjunc-
tivitis. Allergic conjunctivitis is a multifactorial condition with 
a panoply of causes, presentations, and degrees of discomfort. 
While these topical multimechanism agents share many proper-
ties, the percentage of patients responding to any one of these 
ranges from 33% to 75%. Patients, who do not respond to one 
drug in this class, or are unable to tolerate it, may find another 
drug in this class to be efficacious and tolerable.
As a broad-spectrum agent, azelastine offers many of 
these desirable properties for management of ocular aller-
gies. Because it can often produce maximal effect with just 
twice-daily dosing, azelastine is a particularly good choice 
for the allergic population in whom minimizing exposure to 
topical products and preservatives are a key concern. Even 
though it was rated somewhat less efficacious and may sting 
briefly after instillation in one out of three patients,4 many 
patients experienced full benefit, which they considered to 
be more important than the transient stinging sensation upon 
instillation of the azelastine eyedrop. Furthermore, with con-
venient administration schedules, comfort, and effectiveness, 
topical therapy is associated with excellent patient compli-
ance, which is a fundamental determinant of efficacy.
Nonpharmacologic management is also an essential 
component in the care of patients with ocular allergy. Non-
pharmacologic interventions include strategies to reduce 
exposure to inciting antigens, management of dry eye, and 
even dietary intervention. These prophylactic measures 
should be continued during topical therapy until allergy 
symptoms have abated, and to decrease the likelihood of a 
relapse in the continuing presence of allergens.
We cannot actually cure the allergy just yet. It is impor-
tant for patients to understand this. Allergy symptom treat-
ment may not be as glamorous or dramatic as cataract or 
refractive surgery or the reversal of life-threatening status 
asthmaticus, but favorable therapeutic results make patients 
happy, productive, and comfortable. By using cost-effective 
treatment regimens, both practical and medical, and enlist-
ing the help of family members and other physicians, we 
can achieve acceptable control of most allergic symptoms. 
Not bad for a 40 µL drop in a 6 cc eye dropper bottle.
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